Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine UCLA
Dates
study started
completion around

Description

Summary

The purpose of this study is to evaluate the efficacy and safety of Nipocalimab versus placebo in participants with active idiopathic inflammatory myopathies (IIM).

Official Title

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

Keywords

Myositis, Glucocorticoids, Nipocalimab

Eligibility

Locations

  • University of California Irvine Medical Center
    Orange California 92868 United States
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
    Torrance California 90502 United States
  • Attune Health Autoimmune and Inflamation Care and Research
    Beverly Hills California 90211 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Janssen Research & Development, LLC
ID
NCT05379634
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 36 people participating
Last Updated